Author Archives: admin


Stem Cell Therapy and Regenerative Medicine with Dr. Mayo …

Dr. Friedlis tells the Patch about his Stem Cell Arts practice, an affiliate of National Spine and Pain Centers and its cutting edge techniques that patients overcome chronic pain with non-surgical procedures.

Patch: What is Stem Cell Therapy and Regenerative Medicine (or Platelet Therapy)?

Dr. Friedlis: Stem Cell Therapy and Platelet Therapy / platelet rich plasma (PRP) therapy are revolutionary non-invasive medical procedures that relieve pain. These treatments promote the long lasting healing of musculoskeletal conditions for common injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis, using the natural healing properties of the patient's own stem cells. Stem cells are used to heal damaged tissue, ligaments, cartilage, and bone while managing pain. The stem cells are harvested from the patient's own hip bone marrow via syringe, concentrated, and then re-injected into injured tissue in other areas of the body. These stem cells then act as a 'booster' for the body's natural healing process and enable the patient to heal without the use of foreign materials or surgery. These rapidly emerging techniques are showing exciting success with osteoarthritis of the knee, shoulder, hip, and spine, rotator cuff tears, chronic plantar fasciitis, anterior cruciate ligament (ACL) injuries, pelvic pain and instability, back and neck injuries, tennis elbow, ankle sprains, tendonitis, and ligament sprains.

Patch: What can Stem Cell Therapy and Regenerative Procedures do for a prospective patient?

Dr. Friedlis: Stem Cell Therapy and Regenerative Procedures are viable alternatives for individuals who may be considering elective surgery or joint replacement due to injury or arthritis, we offer these procedures to patients wishing to avoid lengthy periods of downtime and painful rehabilitation that come with invasive surgeries.

Patch: Am I Too Old or Too Injured to have Stem Cells Work for me?

Dr. Friedlis: Age and level of injury are not typically a factor in a regenerative procedure because the treatment is noninvasive and stimulates the body's natural healing mechanisms. The risk of surgical treatment for older patients or those with existing injuries is greatest during the recovery period. Because stem cell therapy is non-invasive, complications during the recovery are not a concern.

Typically, patients come see us for one of three reasons. The first of those being that the patient is younger, and due to either a genetic condition or injury, is facing joint replacement at an early age. Often what happens, over long periods of time, is that the replacement joint will experience wear and the patient will need another replacement surgery to remedy the problem. By seeking regenerative treatment, we are able to help our younger patient manage the pain enough to delay the need for surgery. That way the patient will only have to undergo one joint replacement surgery in their lifetime instead of two or three.

The second reason many patients come is that they cannot afford to take the required amount of downtime necessary to recover from traditional surgical treatments for musculoskeletal ailments. Because our treatment is noninvasive, patients are able to quickly recover and begin the healing process, allowing them to get back to their everyday lives.

The third type of patient that visits us are those who have already had surgical treatments to help manage their condition, however are still suffering from pain. In partnership with their orthopedic surgeons, we use regenerative therapies in adjunct to their traditional therapy to help the patient manage their pain.

Each patient has a unique situation when they visit us. Because of that, each treatment is customized to meet the individual patient's needs.

Patch: What attracted to you to this industry, and how did you start?

Dr. Friedlis: As a physician in pain management, I became frustrated with the lack of solutions to truly fix my patients. There are many excellent methods to controlling pain using traditional medicine. However, those methods are often used to simply hide the problem. Regenerative medicine enables us to help manage the root cause of the patient's pain by preserving and improving the body's function with little or no downtime. That way our patients can get back to doing the things they love sooner.

Patch: What's the biggest challenge or most difficult moment you've faced in your job?

Dr. Friedlis: I have been among the first to adopt regenerative therapies after much scientific review. The science of these newer procedures and therapies is still not at the level of a double blind study; the most rigorous and expensive research method. So, I would say that one difficulty is facing naysayers who are not open to newer methods for non-surgical treatments that harness the body's ability to heal. Luckily, patients are getting the word out. Our network has a full-time research team studying the outcomes of several thousand patients over the course of several years. The studies are demonstrating positive results, such as pain reduction across the knee, shoulder, hip, and elbow, as well as other joint, ligament, and tendon conditions.

Patch: What advice would you give a person just starting in your industry?

Dr. Friedlis: Regenerative medicine is a very specialized field that requires a significant amount of training. Because of the progressive nature of the practice, unfortunately, the skill and knowledge that you need cannot be obtained through today's standard medical training.

In order to achieve the level of expertise required, you need to be diligent in educating yourself in regenerative medicine and take it upon yourself to stay well versed in the latest advancements in the field. You need to always be scouring the web for blogs and latest findings from people all over the world on the subject matter to keep track of all the advancement that people are making.

Regenerative medicine is a work in progress. However, you have a responsibility to stay on top of the latest and best practices being used globally so you can provide and deliver top quality care to your patients.

What's the best piece of advice you've ever been given?

Dr. Friedlis: The best piece of personal advice I received was to marry my wife. However, on a more professional level, the best piece of advice I received was to always have the courage to think outside of the box when trying to find solutions for your patients. By only sticking to the traditional menu of medical solutions, we as physicians may be missing some important treatments that can make a real difference in our patients' lives. I have been fortunate to find partners in Dr.'s Wagner and Dade, who are like-minded.

Patch: How did you come up with the name of your business?

Dr. Friedlis: The name of our business, Stem Cell Arts, is a direct reflection of what we do. In our practice, Dr. Rodney Dade, Dr. Robert Wagner, and I integrate over a decade of experience in using a patient's own stem cells to manage pain with the science and art required to successfully implement some of today's most progressive medical research and techniques in a rapidly advancing field.

Patch: What's the best part about doing business in your town?

Dr. Friedlis: Living in Potomac, Maryland and working in Chevy Chase, Maryland and Tysons/McLean, Virginia allows me to meet a variety of extremely interesting, engaging, and diverse people. The most gratifying aspect of what I do is helping patients get back to the things they desire to dobe it working, exercising, travelingyou name it. I also enjoy treating multiple members of one family and getting to know them well.

Patch: If you were to get an indulgent snack in your town, where would you go and what would you get?

Dr. Friedlis: I would have to say Moby Dicks. The food is healthy, prepared fresh, and well done. Overall, I find it very satisfying.

Here is the original post:
Stem Cell Therapy and Regenerative Medicine with Dr. Mayo ...

3 Ways Predictive Analytics is Advancing the Healthcare Industry – HealthITAnalytics.com

Source: Getty Images

July 21, 2020 -As the healthcare industry has increasingly aimed to deliver proactive, quality care, predictive analytics models have emerged as viable tools for improving outcomes and cutting costs.

From mapping the spread of infectious diseases, to forecasting the potential impact of certain conditions, predictive analytics tools can help organizations stay one step ahead in an unpredictable industry.

Researchers and provider organizations are applying predictive analytics techniques to improve practices across the care continuum, leading to more informed decision-making and better patient care.

Throughout the COVID-19 pandemic, predictive analytics models have played a major role in helping healthcare leaders track and prepare for the spread of the virus.

Researchers at the University of Texas Health Science Center at Houston (UTHealth) recently developed a new COVID-19 tracking tool that leverages predictive modeling to help mitigate the impact of the virus.

READ MORE: Predictive Analytics Model Examines Droplets to Map COVID-19 Spread

We created this interactive public health dashboard because we wanted to help our fellow Texans. By understanding future trends of this virus, it can help aid in the effective management of local resources, said Jos-Miguel Yamal, PhD, an associate professor of biostatistics and data science at UTHealth School of Public Health in Houston and one of the projects lead developers.

The interactive tool is freely available to the community to inform public health decision-making across the state. In addition to the figures for the daily number of confirmed cases throughout the state, the tool provides charts that show the measure of contagiousness of each COVID-19-positive individual in the region.

The dashboard identifies the current hot spots, predicts future spread both at the state and county level, and houses relevant public health resources. It can effectively inform decision-makers across Texas to help mitigate the spread of COVID-19, said Shreela Sharma, PhD, a member of the research team and professor of epidemiology, human genetics, and environmental sciences at UTHealth School of Public Health in Houston.

A team at CommonSpirit Health has also leveraged predictive analytics tools to help public health officials better prepare for the spread of COVID-19. The organization used de-identified cell phone data, public health information, and data from its own care sites to build predictive models and gain insight into COVID-19 dips and surges.

We started looking at the first peaks of the virus, and there were enough cases for us to do some modeling and prediction. Now, just three months later, we're looking at the same virus as people are getting back together and the contact rate is going up. And we're trying to manage this resurgence in our markets, Joseph Colorafi, MD, System VP of Clinical Data Science for CommonSpirit Health, told HealthITAnalytics.

READ MORE: Predictive Analytics Model Forecasts COVID-19 Risk, Outcomes

Researchers have also applied predictive analytics techniques to manage and stem the onset of chronic conditions.

A study recently published in Diabetes Care showed that building predictive models with patient data, including history of comorbidities and medications, can determine the five- to ten-year life expectancy of older adults with diabetes and help providers develop personalized treatment plans.

The guidelines don't give doctors guidance for how to decide whether or not people fall into these different bins for life expectancy,saidKevin Griffith, research analyst at the Department of Veterans Affairs (VA) Boston Healthcare System.

Furthermore, clinicians are notoriously inaccurate in predicting life expectancy, with studies frequently showing both over- and underestimating. We developed models with high predictive validity of future mortality in a large sample of older veterans with diabetes.

The models could help providers use shared decision-making to establish A1c target ranges that balance treatment and risks. The models could also serve as comprehensive clinical decision support tools for diabetes management and care.

READ MORE: 60% of Healthcare Execs Say They Use Predictive Analytics

Predictive analytics tools can also help improve chronic disease prevention. Researchers from Mount Sinai recently developed new predictive analytics tools and identified environmental risk factors that could lead to a new understanding of what triggers Crohns disease.

Early identification of individuals at high risk for disease development could allow for close monitoring and interventions to delay, attenuate, or even halt disease initiation, said Jean-Frederic Colombel, MD, Professor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai and Co-Director ofMount Sinais Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center.

This is highly relevant as we seek to predict and prevent IBD, which continues to sharply increase in numbers across the globe. In the absence of a cure, our clinical strategy will center on aggressive and innovative mechanisms to predict and prevent the disease.

Using predictive analytics models, researchers and provider organizations can also prepare for potential future trends and events that impact clinical care delivery.

In a study published in the Lancet Public Health, researchers showed that a big data model projected that without any changes in alcohol consumption or interventions to address high-risk drinking, deaths from alcohol-related liver disease will rise significantly in the US.

The studys results revealed that lawmakers should consider taking measures to curb high-risk drinking across the country.

Our study underscores the need to bring alcohol-related disease to the forefront of policy discussions and identify effective policies to reduce high-risk drinking in the US,saidsenior authorJagpreet Chhatwal, a senior scientist at theMGH Institute for Technology Assessmentand an assistant professor at Harvard Medical School.

On a smaller scale, researchers can use predictive analytics tools to get ahead of adverse healthcare events in individual patients. Recent research funded by the National Institute on Minority Health and Health Disparities showed that a simple risk prediction model helped forecast stroke risk in adult patients who have migraine with aura.

The model could help providers identify patients at high risk and intervene before the stroke occurs.

People who have migraine with aura are at increased risk for anischemic stroke, said Souvik Sen, MD, MPH, study co-author, and professor and chair of the neurology department at the University of South Carolina School of Medicine in Columbia, South Carolina. With our new risk-prediction tool, we could start identifying those at higher risk, treat their risk factors and lower their risk of stroke.

Read more here:
3 Ways Predictive Analytics is Advancing the Healthcare Industry - HealthITAnalytics.com

SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike…

This article was originally published here

Stem Cell Rev Rep. 2020 Jul 20. doi: 10.1007/s12015-020-10010-z. Online ahead of print.

ABSTRACT

Angiotensin-converting enzyme 2 (ACE2) plays an important role as a member of the renin-angiotensin-aldosterone system (RAAS) in regulating the conversion of angiotensin II (Ang II) into angiotensin (1-7) (Ang [1-7]). But at the same time, while expressed on the surface of human cells, ACE2 is the entry receptor for SARS-CoV-2. Expression of this receptor has been described in several types of cells, including hematopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs), which raises a concern that the virus may infect and damage the stem cell compartment. We demonstrate for the first time that ACE2 and the entry-facilitating transmembrane protease TMPRSS2 are expressed on very small CD133+CD34+LinCD45 cells in human umbilical cord blood (UCB), which can be specified into functional HSCs and EPCs. The existence of these cells known as very small embryonic-like stem cells (VSELs) has been confirmed by several laboratories, and some of them may correspond to putative postnatal hemangioblasts. Moreover, we demonstrate for the first time that, in human VSELs and HSCs, the interaction of the ACE2 receptor with the SARS-CoV-2 spike protein activates the Nlrp3 inflammasome, which if hyperactivated may lead to cell death by pyroptosis. Based on this finding, there is a possibility that human VSELs residing in adult tissues could be damaged by SARS-CoV-2, with remote effects on tissue/organ regeneration. We also report that ACE2 is expressed on the surface of murine bone marrow-derived VSELs and HSCs, although it is known that murine cells are not infected by SARS-CoV-2. Finally, human and murine VSELs express several RAAS genes, which sheds new light on the role of these genes in the specification of early-development stem cells. Graphical Abstract Human VSELs and HSCs express ACE2 receptor for SARS-CoV2 entry. Interaction of viral spike protein with ACE2 receptor may hyperactivate Nlrp3 inflammasome which induces cell death by pyroptosis. SARS-CoV2 may also enter cells and eliminate them by cell lysis. What is not shown since these cells express also Ang II receptor they may hyperactivate Nlrp3 inflammasome in response to Ang II which may induce pyroptosis. Our data indicates that Ang 1-7 may have a protective effect.

PMID:32691370 | DOI:10.1007/s12015-020-10010-z

Visit link:
SARS-CoV-2 Entry Receptor ACE2 Is Expressed on Very Small CD45(-) Precursors of Hematopoietic and Endothelial Cells and in Response to Virus Spike...

Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth, Industry Outlook: Post COVID-19 Investors Eye Bigger-Than-Expected | Orion Pharma,…

Global Amyotrophic Lateral Sclerosis Treatment Market By Disease Type (Benign Focal Amyotrophy of ALS, Infantile Spinal Muscular Atrophy, Juvenile Spinal Muscular Atrophy, Kugelberg-Welander Disease, Primary Lateral Sclerosis, Progressive Bulbar Palsy, Spinal Muscular Atrophy, Upper Motor Neuron Disease, Werdnig-Hoffman Disease, Wohlfart-Disease), Drug Type (Riluzole and Edaravone (Radicava)), By Distribution Channel (Hospital Pharmacies, and Retail & Online Pharmacies), Treatment type (Chemotherapy, Stem cell therapy) End- User (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends & Forecast to 2026

Get a sample copy of report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-amyotrophic-lateral-sclerosis-treatment-market

Few of the major competitors currently working in the amyotrophic lateral sclerosis treatment market are Sanofi (France), Mitsubishi Tanabe Pharma Corporation (Japan), BrainStorm Cell Limited (US), ViroMed Co., Ltd (South Korea), Ionis Pharmaceuticals (US), Genervon Biopharmaceuticals, LLC (US), Biogen (US), ORPHAZYME A/S (Denmark), Orion Pharma (Finland), Kringle Pharma, Inc. (Japan), Aquestive Therapeutics (US), Apotex Inc (Canada), Bausch Health Companies Inc. (Canada), Neuralstem, Inc. (US), Implicit Bioscience (Australia), F. Hoffmann-La Roche Ltd (Switzerland), TREEWAY (Netherlands), CYTOKINETICS, INC. (US), AB Science (France), Advanz Pharmaceutical (Canada) and few among others.

Market Analysis:Global Amyotrophic Lateral Sclerosis Treatment Market

Global amyotrophic lateral sclerosis treatment market is expected to rise gradually to an estimated value of USD 3.6 billion by 2026, registering a CAGR of 21.6% in the forecast period of 2019-2026 with the annual sales of USD 0.75 billion in the year of 2018. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.

Market Definition:Global Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease, also known as motor neuron disease (MND) and Lou Gehrigs disease that affects nerve cells (motor neurons) of brain, brain stem and spinal cord that controls voluntary muscles. This disease is progressive in nature.

According to Centers for Disease Control and Prevention, there were approximately 14,000 15,000 people in US in 2016 having ALS, almost more than half of these cases could have been avoided with the availability of proper medical treatment. This significant number is expected to act as a driver to the market growth.

Market Drivers

Market Restraints

Make an Inquiry Before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-amyotrophic-lateral-sclerosis-treatment-market

Segmentation: Global Amyotrophic Lateral Sclerosis Treatment Market

By Disease Type

ByDrug Type

By Distribution Channel

By Treatment Type

By End- User

ByGeography

Key Developments in the Market:

Competitive Analysis:

Global amyotrophic lateral sclerosis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of amyotrophic lateral sclerosis treatment market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

Customization of the Report:

Get a discount on this research report @https://www.databridgemarketresearch.com/request-a-discount/global-amyotrophic-lateral-sclerosis-treatment-market

More:
Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Growth, Industry Outlook: Post COVID-19 Investors Eye Bigger-Than-Expected | Orion Pharma,...

Dr. Komrokji on the Current Treatment Landscape in MDS – OncLive

Rami Komrokji, MD, discusses the current treatment landscape in myelodysplastic syndrome.

Rami Komrokji, MD, professor, Medicine and Oncologic Sciences, College of Medicine, University of South Florida, senior member, Malignant Hematology and Experimental Therapeutics Program, and head of the Leukemia and MDS Section, Moffitt Cancer Center, discusses the current treatment landscape in myelodysplastic syndrome (MDS).

Hypomethylating agents (HMAs) such as azacitidine and decitabine have been the frontline standard of care for patients with MDS for over a decade, says Komrokji. While these agents improve survival and delay leukemic transformation, they are only active in about half of patients with MDS for around 1 year.

Allogeneic stem cell transplantation (allo-SCT), the only curative option for patients with MDS, is typically reserved for patients with higher-risk disease, explains Komrokji. Many patients with MDS are ineligible for allo-SCT due to disease risk, age, or comorbidities.

Patients with high-risk disease, including those with p53 mutations, tend to have poor survival despite treatment with HMAs or intensive chemotherapy, Komrokji says.

Future research efforts should focus on improving response rates and the durability of response with HMAs, as well as developing novel agents for patients who progress on HMAs, concludes Komrokji.

Read more:
Dr. Komrokji on the Current Treatment Landscape in MDS - OncLive

Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit – PRNewswire

LEXINGTON,Mass., July 21, 2020 /PRNewswire/ --Agenus Inc.(NASDAQ: AGEN), an immuno-oncology(I-O) companywith apipelineofimmunecheckpointantibodies, adoptive cell therapies and cancer vaccines,announcedtoday that Dr. Jennifer Buell, President and COO of Agenus, and Dr. Manuel Hidalgo, Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian Hospital, will discuss AgenTus Therapeutics, Inc.'s (a subsidiary of Agenus) allogeneic iNKT cell therapy approach for infectious diseases at the B. Riley Virtual Infectious Disease Summit Therapeutics Day on a Panel entitled Pursuing Curative Cell Therapy Approaches.

Date: Tuesday, July 21, 2020

Time: 3:00 PM 4:00 PM ET

Title: Pursuing Curative Cell Therapy Approaches Cell Therapy has become a fast-changing field after becoming a powerful clinical therapy for late line cancer patients with the approval of the first generation CD19+ CAR T cell treatments (Yescarta and Kymriah). Participants in the panel include AgenTus Therapeutics, a biotech company and subsidiary of Agenus Inc. developing new cancer treatments, including AGENT-797, an early unmodified allogeneic iNKTcell therapy, Magenta Therapeutics, a cell therapy company developing novel cell therapies including MGTA-456, a stem -cell production therapy, and SQZ Biotechnologies Company, a biotech company developing oncology drugs including APC HPV, an autologous based therapy for several types of cancer.

Agenus Inc.Jennifer Buell, Ph.D. President and Chief Operating Officer Manuel Hidalgo, M.D. Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/New York Presbyterian

Excision BioTherapeuticsDaniel Dornbusch - Chief Executive Officer

Pluristem Therapeutics (PSTI)Racheli Ofir Vice President of Research & IP

About AgenTus Therapeutics, Inc.AgenTus Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of breakthrough allogeneic iNKT cells in the unmodified and modified with engineered receptors, such as T cell receptors (TCRs) and Chimeric Antigen Receptors (CARs), designed to supercharge the human immune system cells to seek and destroy cancer. AgenTus also aims to advance adoptive cell therapy formats which would enable off-the-shelf living drugs. AgenTus has locations inLexington, MAandCambridge, UK. For more information, please visitwww.agentustherapeutics.com.

About Agenus Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer and infections. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit http://www.agenusbio.com and our Twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.

Contact:Agenus Inc.Jennifer Buell, PhD 781-674-4420 [emailprotected]

SOURCE Agenus Inc.

See the article here:
Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the B. Riley Virtual Infectious Disease Summit - PRNewswire

Hypoxia Market 2020 How the Market has witnessed Substantial Growth in Recent Years? – Cole of Duty

Data Bridge Market Research Market Research (DBMR) has published a latest market research report on Global Hypoxia Market . The global report is prepared in collaboration with the leading industry experts & dedicated research analyst team to provide an enterprise with in-depth market insights and help them to take crucial business decisions. This report covers current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

Hypoxia Market business research report aids to stay up-to-date about the entire market and also offer holistic view of the market. Market definition, market segmentation, key developments in the market, competitive analysis & research methodology are the major topics covered in this report which are thoroughly studied with the best tools and techniques. Analysts have used a SWOT analysis and a Porters five forces analysis to estimate the global Hypoxia market thoroughly. Both these tools ensure accurate assessment of the market & including the intensity of the competitive rivalry present in the market. This market analysis enables readers to deal with a wide range of business issues and come to logical conclusions that can be used for making well-informed decisions.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypoxia-market&rp

Market Analysis: Global Hypoxia Market

Global hypoxia market estimated to register substantial CAGR in the forecast period of 2019 to 2026. The report contains data for historic year 2017 and the base year of calculation is 2018. The growth of the market can be attributed to the strategic initiatives by the market players.

Key Market Competitors:

Some of the major companies functioning in globalhypoxia marketareAileron Therapeutics, Inc., CASI Pharmaceuticals Inc, Spotlight Labs,LLC, F.Hoffmann-La Roche Ltd, AXXAM S.p.A, HypOxygen, Oncolmmune, Nasdaq,Inc, Hancock Medical Inc, Phio Pharmaceuticals, International Marketers For Scientific Equipments & Technologies, Coy Laboratory Products, Inc, Thermo Fisher Scientific, Baker, STEMCELL Technologies Inc, Bioxia, Hypxico Europe, Merck KGaA among others

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-hypoxia-market&rp

Market Definition: Global Hypoxia Market

Hypoxia is a condition in which the body does not get enough oxygen for supply and oxygen therapy is provided in the complete absence of oxygen, so that the tissue can get oxygen in sufficient manner. It is diagnosed by physical examination and by using oxygen monitors, which are also known as pulse oximeters. It is used in various applications such as in hospitals, specialty clinics.

Hypoxia Market Drivers :

Hypoxia Market Restraints :

Segmentation:Global Hypoxia Market

Hypoxia Market : By Type

Hypoxia Market : By Disease Type

Hypoxia Market : By End User

Hypoxia Market : By Distribution Channel

Hypoxia Market : By Geography

Key Developments in the Hypoxia Market :

Competitive Analysis:

Global hypoxia market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of hypoxia market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Research Methodology:Global Hypoxia Market

Data assemblage and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more pleaserequest an analyst callor can drop down your enquiry.

The key research methodology used byDBMR researchteam is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents :

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.

Reasons to Purchase this Report :

Customization of the Report :

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hypoxia-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

Read the original here:
Hypoxia Market 2020 How the Market has witnessed Substantial Growth in Recent Years? - Cole of Duty

Human Embryonic Stem Cells (HESC) Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 – Connected…

The Global Human Embryonic Stem Cells (HESC) Market report by DataIntelo.com provides a detailed analysis of the area marketplace expanding; competitive landscape; global, regional, and country-level market size; impact market players; market growth analysis; market share; opportunities analysis; product launches; recent developments; sales analysis; segmentation growth; technological innovations; and value chain optimization. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report.

Request Free Sample Of This Report At: https://dataintelo.com/request-sample/?reportId=94347

Market Segmentation

The Global Human Embryonic Stem Cells (HESC) Market has been divided into product types, application, and regions. These segments provide accurate calculations and forecasts for sales in terms of volume and value. This analysis can help customers increase their business and take calculated decisions.

By Product Types, Totipotent Stem Cells Pluripotent Stem Cells Unipotent Stem Cells

By Applications, Research Clinical Trials Others

By Regions and Countries, Asia Pacific: China, Japan, India, and Rest of Asia Pacific Europe: Germany, the UK, France, and Rest of Europe North America: The US, Mexico, and Canada Latin America: Brazil and Rest of Latin America Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Human Embryonic Stem Cells (HESC) market. This section offers information on the sales growth in these regions on a country-level Human Embryonic Stem Cells (HESC) market.

The historical and forecast information provided in the report span between 2018 and 2026. The report provides detailed volume analysis and region-wise market size analysis of the market.

Competitive Landscape of the Human Embryonic Stem Cells (HESC) Market

The chapter on competitive landscape provides information about key company overview, global presence, sales and revenue generated, market share, prices, and strategies used.

Major players in the global Human Embryonic Stem Cells (HESC) Market include ESI BIO Thermo Fisher BioTime MilliporeSigma BD Biosciences Astellas Institute of Regenerative Medicine Asterias Biotherapeutics Cell Cure Neurosciences PerkinElmer Takara Bio Cellular Dynamics International Reliance Life Sciences Research & Diagnostics Systems SABiosciences STEMCELL Technologies Stemina Biomarker Discovery Takara Bio TATAA Biocenter UK Stem Cell Bank ViaCyte Vitrolife

To Purchase This Report: https://dataintelo.com/checkout/?reportId=94347

The Human Embryonic Stem Cells (HESC) Market Report Addresses:

The Report Provides:

For Best Discount on Purchasing this Report Visit https://dataintelo.com/ask-for-discount/?reportId=94347

About DataIntelo: DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex Mathews Address: 500 East E Street, Ontario, CA 91764, United States. Phone No: USA: +1 909 545 6473 | IND: +91-7000061386 Email: [emailprotected] Website: https://dataintelo.com

Natalia is Business Writer Carrying A Vast Experience Over a Decade , She Helps TechinFeed Blog with her Expertise Business Articles

Go here to see the original:
Human Embryonic Stem Cells (HESC) Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 - Connected...

Scientists Created Tiny Organs That Could Bring an End to Animal Testing – Interesting Engineering

Scientists have created organs that are one-millionth the size of a regular human organ.

An entire system of miniature organs known as "organoids" has been created by scientists at the Wake Forest Institute for Regenerative Medicine. In doing so they have built the world's most sophisticated lab model of the human body.

The whole point of the system is that these tiny organs, or "organoids", can successfully determine if a pharmaceutical product is toxic to the human body or not, which would also help put an end to animal testing. The world of organoids is not completely new, however, the Wake Forest experiment has been dubbed as the"World's Most Sophisticated Lab Model of the Human Body."

Their findings were published in the scientific journal Biofabrication.

SEE ALSO: NASA EXPERIMENT: ASTRONAUTS GROWING ORGANS ABOARD THE INTERNATIONAL SPACE STATION

Developing new medical drugs requires a lot of money, time, and sometimes the lives of a great many animals.According to a report published in theAmerican Journal of Gastroenterology, it costs an estimated $868 million to $1.24 billion to develop a drug. It's even more disheartening when drugs that have cost a lot of time, effort, money, and animal lives have to then be pulled off of the shelf, as they can't adequately predict whether or not the substance will be toxic to humans in the longer term.Now, a minute innovation may provide some huge answers.

Researchers from the Wake Forest Institute for Regenerative Medicine and Ohio State Universityhave developed an entire system that replicates human organs in microscopic sizes. Everything from the liver, to the heart, and lungs are able to be recreated in tiny sizes so as to improve pharmaceuticals looking to run tests that currently require petri dishes or animals.

The system was then embedded onto a computer chip.

"We tried to make the organs very much related to how they look inside of you, very similar to how they would look on the macro scale if we were implanting them into you," study co-author Anthony Atala, chair and institute director of the Wake Forest Institute for Regenerative Medicine toldPopular Mechanics.

These mini-organs have been dubbed "organoids" and are 3D tissue cultures that are sourced from stem cells. To give an estimation of just how small these are, they range from the size of less than the width of a strand of hair to five millimeters.

This isn't the first time researchers have created organoids in a lab, Atala himself has been working on organoids since the early 2000s. However, this is the first time that they have been able to successfully demonstrate levels of toxicity to humans.

Atala and his team focused on building a system as close to the real human system as possible. For instance, the organoid heart pumps roughly 60 times per minute, similar to the human heart. The human liver contains five major cell types, as does the organoid one.

Once the organoids are grown, the researchers can then run tests on them. This is where animal testing could be eradicated.

Atala mentioned"We can test chemotherapies to see which would work best for a given patient. This is great for personalized medicine."This is a huge step forward in the field of medicine.

Interestingly, the foundations for organoid research can be dated back to 1906, when Ross Granville Harrison first adapted a three-dimensional cell culture method called the "hanging drop" for use in the study of embryonic tissues.

For the uninitiated, Harrison was an American biologist and anatomist who is credited for growing the first artificial nerve tissue culture. His contributions would be the guiding path towards the discovery of the nerve growth factor in the 1950s, a vital building block to our study of stem cells today. Over the past 15 years, though there are still limitations, organs can be grown in a lab, and the field is continuing to innovate.

But how do they do it? Within a laboratory setting, researchers must first isolate small samples of human organs and tissues to ensure that tiny organs have the same functionality. What does this mean? As mentioned above, if you were to create an organoid heart, it would pump at the same rate as a human heart. This is why the world of tiny organs is so exciting.

Other research teams outside Ohio State University and the Wake Forest Institute for Regenerative Medicine have also created organoids. In addition to the miniature lab model of the human body, which is useful for testing drugs, organoids also have the capacity to act as organ replacements.

So what have researchers grown so far?

The Center for Regenerative Medicine created a pair of working lab-grown kidney organoids. These organs were then transplanted into rats by researchers. Accordingto the research articlewhere it mentions the study in detail, "Approximately 100,000 individuals in the United States currently await kidney transplantation, and 400,000 individuals live with end-stage kidney disease requiring hemodialysis."

Transplantable, permanently replaceable kidneys would help address this current problem. To do this, the bioengineered graft would need to have the kidney's architecture and function and permit perfusion, filtration, secretion, absorption, and drainage of urine.

Above all, it would need to be compatible with the recipient, to avoid rejection. Researchers were not only able to create these tiny kidneys and transplant them into rats but on transplanting the kidney, the new organs were able to filter blood and produce urine successfully.

The MRC Centre for Regenerative Medicine has also made progress in the world of organoids, creating tiny livers. In the study, researchers were able to take liver stems, or hepatic progenitor cells, to regrow damaged livers in mice. How did this work? Researchers extracted stem cells from a group of healthy mice. They then took these cells and had them mature in the lab. Once mature, the cells were transplanted back in the mice without any liver failure. The entire process took about three months.

Researchers at Cincinnati Children's Hospital Medical Center have grown organoid intestines.

Using pluripotent stem cells, researchers were able to grow human intestinal tissue in the lab. However, compared to other processes mentioned in this article, they did something different. To get the tissue to adopt adult tissue architecture, researchers transplanted the tissue to the kidney of a mouse, where it matured within the animal.

Researchers at Cincinnati Children's Hospital Medical Center hope that this method could ultimately be used for the treatment of gastrointestinal diseases globally.

Yes, we can. Created also by a research team at Cincinnati Children's Hospital Medical Center, researchers have found a way to grow three-dimensional gastric tissue. The process involves taking human pluripotent stem cells and coaxing them into becoming stomach cells. The result? Organoids that were only three millimeters in diameter. Tiny organs like these could be used to study various disease models and their effects on the stomach.

According to theresearch team, "Gastric diseases, including peptic ulcer disease and gastric cancer, affect 10% of the world's population and are largely due to chronic Helicobacter pylori infection.

Species differences in embryonic development and architecture of the adult stomach make animal models suboptimal for studying human stomach organogenesis and pathogenesis, and there is no experimental model of the normal human gastric mucosa."

The darker side of drug testing usually involves animal testing. For the uninitiated, animal testing often centers around the procedures performed on living animals for the research into basic biology and diseases, assessing the effectiveness of new medicinal products, and testing the health and environmental safety of consumer and industry products.

This can include cosmetics, household cleaners, food additives, pharmaceuticals, and industrial/agrochemicals.

Sadly, animals that are part of these procedures tend to be killed or may even be reused in other experiments. According to theHumane Society International, an estimated 115 million animals are tested on worldwide each year.

As more tiny organs are developed in labs across the world, we will be able to slowly tackle the ethical challenges of animal testing, while creating better and safer drugs for humans. Even more so, the world of organoids is a precursor to the coming age of lab-ready organ transplants.

For the latest innovations in Medical Technology, be sure to stop by here.

Originally posted here:
Scientists Created Tiny Organs That Could Bring an End to Animal Testing - Interesting Engineering

In Cells and Whole Organisms, Repair Mechanisms Imply Foresight, Not Evolution – Discovery Institute

Photo credit: JC Gellidon via Unsplash.

Cells and organisms come pre-equipped with repair mechanisms. It takes foresight to make complex tools and procedures that can restore the functions of other tools. A blind process like evolution can only see the immediate present; it would be unconcerned about what happens next. Repair implies something worth saving. The more delicate the product, the more elaborate the maintenance. Live is both worth saving and it is delicate. Predictably, the persistence of life presupposes elaborate repair systems are at work. The following research findings show just how complex some of these repair mechanisms are.

Here is a kind of repair strategy that truly would require foresight. A skilled orthopedic surgeon can look at a broken bone and, through years of training, know that before setting it, he needs to make the break worse. In a compound fracture, for instance, bending the bone farther can allow splintered bones to be put back together. Additionally, assistants in the operating room can apply materials or medicines while the surgeon holds the fracture open. Something like that happens in the nucleus or our cells, scientists found at Lawrence Berkeley National Lab. Sometimes, when something is broken, the first step to fixing it is to break it even more. A molecular machine named XPG could be dubbed an orthogenic surgeon (ortho- meaning straight).

We saw that XPG makes a beeline for discontinuous DNA places where the hydrogen bonds between bases on each strand of the helix have been disrupted and then it very dramatically bends the strand at that exact location, breaking the interface that connects bases stacked on top of each other, said Susan Tsutakawa, a structural biologist in the Biosciences Area at Lawrence Berkeley National Laboratory (Berkeley Lab) and first author on the work, published this month in PNAS. The bending activity adds to an already impressive arsenal, as XPG was first identified as a DNA chopping enzyme, responsible for cutting out nucleotide bases with chemical and UV radiation damage. [Emphasis added.]

Natural selection would never do this. First of all, how would XPG recognize a problem that doesnt affect it directly, and how would it know to make a beeline for something elses problem? Then, if by some accident of chance it bent the DNA strand, how would it know how to perform the next surgical step? XPG would be out of a job, rushing toward discontinuous DNA like a blind driver on a demolition derby, breaking genes here and there, killing the organism by a thousand cuts. Instead, look what it does:

An unexpected finding from our imaging data is that the flexible parts of the protein which were previously impossible to examine have the ability to recognize perturbations associated with many different types of DNA damage, said co-author Priscilla Cooper, a biochemist senior scientist in the Biosciences Area. XPG then uses its sculpting properties to bend the DNA in order to recruit and load into place the proteins that can fix that type of damage.

The scientists call this a protein with many jobs that is more like a master sculptor than a demolition crew. Without XPG, a person can incur devastating symptoms of diseases. Some of these fatal syndromes caused by faulty XPG are described in the press release. Often single amino acid substitutions can destabilize the entire protein, they say. If that doesnt clinch the case for design, consider also that the Lawrence Berkeley team found that XPG cooperates with other repair machines like BRCA1 and BRCA2. An entire operating-room team has the foresight to perform orthogenic surgery on DNA. The Darwin-free paper is published in PNAS.1

The brain is busier than a city all the time, even in sleep. Amidst all the clamor, one issue cannot be overlooked: how to dispose of dead cells. A recent article at Evolution News described how the cellular morgue takes care of the problem. In the brain, it is even more vital to quickly eliminate dead cells. A team at Yale School of Medicine heard music inside the skull: they found that astrocytes and microglia perform orchestrated roles and respect phagocytic territories during neuronal corpse removal in the brain. Each player knows its part.

Cell death is prevalent throughout life; however, the coordinated interactions and roles of phagocytes during corpse removal in the live brain are poorly understood. We developed photochemical and viral methodologies to induce death in single cells and combined this with intravital optical imaging. This approach allowed us to track multicellular phagocytic interactions with precise spatiotemporal resolution. Astrocytes and microglia engaged with dying neurons in an orchestrated and synchronized fashion. Each glial cell played specialized roles: Astrocyte processes rapidly polarized and engulfed numerous small dendritic apoptotic bodies, while microglia migrated and engulfed the soma and apical dendrites. The relative involvement and phagocytic specialization of each glial cell was plastic and controlled by the receptor tyrosine kinase Mertk Thus, a precisely orchestrated response and cross-talk between glial cells during corpse removal may be critical for maintaining brain homeostasis.

Their research is published in Science Advances.2 This paper was also Darwin-free except for an opening pinch of incense in the first sentence, Cell death is an evolutionarily conserved and ubiquitous process a useless offering that contributes nothing to the science except to show that evolution was not observed.

Every human life has value, even those with genetic defects (and which human being does not suffer from several?). Whats important to the argument for intelligent design from foresight is how carefully the body practices preventative medicine on the developing embryo. Scientists at Caltech point out,

The first few days of embryonic development are a critical point for determining the failure or success of a pregnancy. Because relatively few cells make up the embryo during this period, the health of each cell is vital to the health of the overall embryo. But often, these young cells have chromosomal aneuploidies meaning, there are too many or too few chromosome copies in the cell. Aneuploid cells lead to the failure of the pregnancy, or cause developmental defects such as Down syndrome later in gestation.

Fortunately, these young embryos perform their own quality control before most genetic abnormalities become established:

Researchers have found that the prevalence of aneuploidy is drastically lower as the embryo grows and develops. Using mouse embryos, scientists from the laboratory of Magdalena Zernicka-Goetz, Caltechs Bren Professor of Biology and Biological Engineering, now show that this is because embryos are able to rid themselves of abnormal cells just before and soon after implantation into the uterus, thereby keeping the whole embryo healthy.

It is remarkable that embryos can do this, says Zernicka-Goetz. It reflects their plasticity that gives them the power to self-repair.

The scientists found a double-protection mechanism. Not only are aneuploidy cells detected and eliminated, but healthy cells are stimulated to proliferate, compensating for the loss of unhealthy cells. The research paper, which also fails to give credit to evolution for this wonderful example of foresight and design, appeared in Nature Communications on June 11.3

Even plants, lacking eyes and brains, know how to repair damage. Plants have a handicap that makes repair more difficult: their repair teams cannot migrate to the site of the injury. Austrian scientists discovered a clever way that a plant can send repair enzymes to the rescue when a stem gets wounded.

Plants are sessile organisms that cannot evade wounding or pathogen attack, and their cells are encapsulated within cell walls, making it impossible to use cell migration for wound healing like animals. Thus, regeneration in plants largely relies on the coordination of targeted cell expansion and oriented cell division. Here we show in the root that the major growth hormone auxin is specifically activated in wound-adjacent cells, regulating cell expansion, cell division rates, and regeneration-involved transcription factor ERF115. These wound responses depend on cell collapse of the eliminated cells presumably perceived by the cell damage-induced changes in cellular pressure. This largely broadens our understanding of how wound responses are coordinated on a cellular level to mediate wound healing and prevent overproliferation.

The research is published in PNAS.4 Its satisfying to say, again, that their paper did not give any credit to evolution. This is one way design wins by default: repeated failures of Darwinists to show up for the game constitutes abdication.

The concept of repair presupposes foresight.5 How would a blind, unguided process recognize a problem? Even if a working plant or animal were granted a hypothetical existence by evolution, the easiest thing for natural selection to do when a problem occurs is to let the organism die. Uncaring selection owes it no further existence. As these examples show (and there are many, many more), life comes equipped with repair teams that are even more complex than expected. It is remarkable that embryos can do this, Caltech scientists said. Yale scientists watched a precisely orchestrated response to cell death in the brain. Lawrence Berkeley scientists did not expect to see a master sculptor in the nucleus already known to have an impressive arsenal of abilities able to surgically straighten DNA before their eyes. These are the emotional responses of people astonished by design beyond their dreams. If they attribute these wonders to evolution, their silence speaks volumes.

Read more from the original source:
In Cells and Whole Organisms, Repair Mechanisms Imply Foresight, Not Evolution - Discovery Institute